MedTech Acquisition (OTCMKTS:MTACU) Files 8-K Report with SEC Announcement

MedTech Acquisition, operating as TriSalus Life Sciences, Inc., recently filed an 8-K report with the Securities and Exchange Commission (SEC) on November 14, 2024. In the filing, the company provided insights into its financial results for the quarter ended September 30, 2024, along with notable business updates.

TriSalus Life Sciences reported a significant increase in quarterly revenue, reaching $7.3 million, marking a 42% year-over-year growth. The cumulative revenue for the nine months ended September 30, 2024, stood at $21.2 million, showcasing a substantial 66% surge compared to the same period in the previous year.

The company highlighted various operational achievements, including the launch of the TriNav LV Infusion System and TriGuide Guiding Catheter, aimed at addressing patients with larger vessels and complex cases within the liver embolization market. Additionally, TriSalus initiated the PROTECT registry trial using the TriNav system to target multinodular goiters, expanding the company’s market reach into the thyroid embolization sector.

TriSalus also revealed positive Phase 1 data from the PERIO-01 trial, focusing on patients with uveal melanoma with liver metastases, reflecting promising clinical benefits and sustainable survival rates. The company made strategic decisions to seek partnerships to further develop this indication and outlined a path forward for pertinent studies.

Regarding financial performance, the firm disclosed an operating loss of $8.7 million for the quarter and $28.6 million for the nine months ended September 30, 2024. It reported favorable growth in revenue, improved operational efficiency, and a reduction in operating expenses, contributing to the positive trajectory in financial results.

Looking ahead to 2025, TriSalus is projecting more than 50% revenue growth, anticipating a reduction of over 20% in operating expenses, positive full-year EBITDA, and a shift to positive cash flow in the latter part of the year. The company expressed confidence in its liquidity sources, expecting sufficient funds for operational needs throughout 2025.

TriSalus Life Sciences has scheduled an earnings call for November 14, 2024, at 9:00 a.m. EST to discuss its third-quarter financial results and strategic updates. Interested parties can access the webcast through the company’s investor relations section on its website.

ENDOFARTICLE

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read MedTech Acquisition’s 8K filing here.

About MedTech Acquisition

MedTech Acquisition Corporation does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the healthcare sector in the United States. The company was incorporated in 2020 and is based in Greenwich, Connecticut.